{"filing":{"accession_number":"0001193125-26-390652","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-08","primary_document":"qncx-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-20260908.htm"},"events":[{"id":33313,"run_id":30626,"accession_number":"0001193125-26-390652","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Quince Therapeutics completed the sale of its Italian subsidiary (Quince Therapeutics SpA), intellectual property related to its AIDE/eDSP technology platform, and manufacturing systems to Ayma Therapeutics for $450,000 cash on September 8, 2026. This material divestiture eliminates a significant business line and is expected to reduce annual R\u0026D expenses by $26.6M.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36725,"accession_number":"0001193125-26-390652","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Quince Therapeutics completed the sale of its Italian subsidiary (Quince Therapeutics SpA), intellectual property related to its AIDE/eDSP technology platform, and manufacturing systems to Ayma Therapeutics for $450,000 cash on September 8, 2026. This constitutes a disposition of assets under Item 2.01, representing a material divestiture of a significant business line (the company's proprietary drug encapsulation technology and related subsidiary). The pro forma financial statements show elimination of substantial R\u0026D expenses ($26.6M annually) and a $1.7M gain on the sale, indicating this was a material operational and financial event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:14.218512+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":33314,"run_id":30626,"accession_number":"0001193125-26-390652","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Charles Ryan, the Company's President, departed on September 8, 2026, with a Separation Agreement providing $1,014,489.04 in severance comprising 18 months base salary, 150% pro-rated bonus, and COBRA premiums.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36726,"accession_number":"0001193125-26-390652","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Charles Ryan, the Company's President, departed on September 8, 2026, with a Separation Agreement providing $1,014,489.04 in severance (18 months base salary, 150% pro-rated bonus, and COBRA premiums). The Item 5.02 disclosure centers on the departure itself and associated severance terms, making this an executive departure event material to investors assessing leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:14.218512+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36725,"accession_number":"0001193125-26-390652","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Quince Therapeutics completed the sale of its Italian subsidiary (Quince Therapeutics SpA), intellectual property related to its AIDE/eDSP technology platform, and manufacturing systems to Ayma Therapeutics for $450,000 cash on September 8, 2026. This constitutes a disposition of assets under Item 2.01, representing a material divestiture of a significant business line (the company's proprietary drug encapsulation technology and related subsidiary). The pro forma financial statements show elimination of substantial R\u0026D expenses ($26.6M annually) and a $1.7M gain on the sale, indicating this was a material operational and financial event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:14.218512+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-09-14"},{"id":36726,"accession_number":"0001193125-26-390652","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Charles Ryan, the Company's President, departed on September 8, 2026, with a Separation Agreement providing $1,014,489.04 in severance (18 months base salary, 150% pro-rated bonus, and COBRA premiums). The Item 5.02 disclosure centers on the departure itself and associated severance terms, making this an executive departure event material to investors assessing leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:14.218512+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-09-14"}]}